Hangzhou Alltest Biotech Second Quarter 2024 Earnings: EPS: CN¥1.00 (vs CN¥0.39 in 2Q 2023)

Simply Wall St · 09/01 00:21

Hangzhou Alltest Biotech (SHSE:688606) Second Quarter 2024 Results

Key Financial Results

  • Revenue: CN¥196.6m (up 30% from 2Q 2023).
  • Net income: CN¥79.1m (up 158% from 2Q 2023).
  • Profit margin: 40% (up from 20% in 2Q 2023).
  • EPS: CN¥1.00 (up from CN¥0.39 in 2Q 2023).
earnings-and-revenue-history
SHSE:688606 Earnings and Revenue History September 1st 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Hangzhou Alltest Biotech shares are up 7.3% from a week ago.

Risk Analysis

Be aware that Hangzhou Alltest Biotech is showing 3 warning signs in our investment analysis and 2 of those make us uncomfortable...